| Eligibility |
Inclusion Criteria:
1. Age = 18 years
2. Eastern Cooperative Oncology Group (ECOG) performance status = 2
3. Urothelial bladder cancer histologically proven (both pure urothelial cancers and
mixed histologic features are allowed)
4. Metastatic patients (AJCC v8: M1a or M1b) documented with contrast-enhanced CT-scanner
of the chest, abdomen and pelvis, either de novo or presenting first distant relapse
following cystectomy (with no local recurrence in the cystectomy bed)
5. Completion of the initial phase (4-6 cycles) of 1st line metastatic treatment
(systemic therapy by chemotherapy and/or immunotherapy by immune check-point inhibitor
according to standard recommendations). Patients having started maintenance therapy
are eligible.
6. No disease progression after the initial phase of first-line metastatic systemic
therapy according to RECIST v1.1
7. No more than 3 residual metastatic lesions following the initial phase of first-line
metastatic systemic therapy:
1. The number of residual lesions is determined on the basis of the imaging modality
for tumor response assessment performed after systemic treatment according to
local habits (CT-scan or 18FDG PET-CT if performed):
In case of response assessment by CT-scanner only: residual lesions are all
remaining visible lesions
In case of response assessment by additional 18FDG PET-CT: residual lesions are
only the lesions with residual hyperfixation
2. Regarding distant lymph nodes metastases:
If evaluation is performed by CT-scanner only, residual lymph nodes are considered
pathological according to one or several criteria among:
- Short axis = 1cm
- Central necrosis
- Heterogeneous contrast enhancement
Residual para-aortic nodes involvement accounts for one lesion, even if several
para-aortic nodes are involved.
Other nodes: each involved node accounts for one lesion.
8. Residual metastases (if applicable) eligible for SBRT in terms of dose constraints to
the organs at risk, with no prior radiotherapy interfering with SBRT
9. 8 weeks or less between last cycle of the initial phase of systemic treatment and
randomization
10. No contraindication to pelvic radiotherapy
11. Signed informed consent
12. Patient able to participate and willing to give informed consent prior performance of
any study-related procedures and to comply with the study protocol
13. Patient affiliated to a Social Health Insurance in France.
Exclusion Criteria:
1. Non-transitional cell histology (Squamous cell carcinoma, adenocarcinoma or
neuroendocrine carcinoma of the bladder)
2. Brain metastases before systemic treatment
3. Liver metastases before systemic treatment
4. Absence of target to be irradiated (i.e. previous cystectomy + no residual lesions
following systemic treatment + no pelvic or para-aortic nodes at metastatic
presentation)
5. Patient with relapse following definitive chemoradiation of the bladder
6. Local recurrence in the cystectomy bed following cystectomy
7. Previous pelvic irradiation
8. Prior radiotherapy near the residual metastatic lesions precluding ablative SBRT
9. Active inflammatory bowel disease
10. Contraindication to SBRT of a lesion due to organ dysfunction; in particular, patients
with lung lesions and documented or suspected interstitial lung disease should not be
included
11. History of scleroderma
12. Current or past history of second neoplasm diagnosed within the last 5 years (except
basocellular carcinoma and prostate cancer incidentally discovered during previous
cystoprostatectomy and pelvic lymph node dissection and with a good prognosis [T stage
<pT3b and Gleason <8 and pN- and post-operative PSA <0.1 ng/mL])
13. Pregnancy or breast feeding or inadequate contraceptive measures
14. Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial
15. Any psychological, familial, geographic or social situation, according to the judgment
of investigator, potentially preventing the provision of informed consent or
compliance to study procedure
16. Patient who has forfeited his/her freedom by administrative or legal award or who is
under legal protection (curatorship and guardianship, protection of justice)
17. Concurrent enrolment in another interventional therapeutic clinical study
|
